To the central content area :::
ECO-Fin
:::
:::Listed Companies > Listed Companies Info. > Main Board Companies > Listed Company Profile

General Stock Board Listed Company Profile

8432 TSH
中文
Company Profile
Chairman CEO Spokesperson Tel Address Date of Listing (Regular)
Chuan Lin Sze Yuan Yang Jung Liang Kao 02-2655-8525 3F-1,No.3-1, Park St., Nangang Dist.,Taipei,Taiwan, R.O.C. 2012/04/30
Industry Main Business
Biotechnology and Medical Care TSH Biopharm Co., Ltd. was one of the business units of TTY Biopharm and formed in 2003, later spin-off from parent company in late 2010. Since its spin-off, TSH Biopharm has been dedicated to the drug development of cardiovascular, gastrointestinal and autoimmune disease as well as the marketing of new drugs in Asia. TSH Biopharm is developing Taiwan and ASEAN New Chemical Entity and Global 505(b)2 products in chronic diseases, especially in CV, GI and autoimmune fields. At the same time, TSH is also establishing sales force in Asian countries, especially in SEA. In order to achieve our goal in a short time. TSH recently expands our collaboration model which does not only reply on CDMO but also in-licensing and co-development. TSH keeps finding out suitable products to enhance our portfolio in target markets and look forward to any kind of collaboration in our interested fields since TSH believes through collaboration can help itself go faster and better.
 
Market Information ( 2024/06/17 )
Shr. Vol. Highest Lowest Closed Change Transaction TurnOver(%) long
margin
balance
(1,000shr.)
Short
margin
balance
(1,000shr.)
90.52 64.20  62.30  63.40  1.20  95 .00 373 1
Trading method Fun
purchase
price or
securities
pneeded
on T day
Announcement of Irregularity
(2024/06/17)
TPEx measures
adopted
(2024/06/17)
With warrants Can be shorted or margined? Detail
Normal N N N N Y Today History
 
Financial Reports
Cash Flows Items
Amount
(NT$ thousand)
Cash flows from operating activities
Cash flows from investing activities
Cash flows from financing activities
Balance
Sheets
Current assets
Non-current assets
Total assets
Current liabilities
Non-current liabilities
Total liabilities
Share capital
Capital surplus
Retained earnings
Other equity interest
Treasury shares
Total equity attributable to owners of parent
Non-controlling interests
Total equity
Book Value per share(NT$)
Comprehensive Income Operating revenue
Operating costs
Gross profit from operations
Operating expenses
Net other income (expenses)
Net operating income
Non-operating income and expenses
Profit before tax
Tax expense
Profit from continuing operations
Profit from discontinued operations
Profit
Other comprehensive income
Comprehensive income
Basic earnings per share
 Auditor's report on latest financial statements: auditor's report:
 More detail:MOPS
 Foreign issuers’ information is disclosed in consolidated statements.